Vagus Nerve Stimulation Shows Positive Treatment Effect in Depression
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 3, 2025 -- Vagus nerve stimulation (VNS) shows a positive treatment effect and improved quality of life (QoL) among patients with treatment-resistant depression (TRD), according to two studies published online Dec. 18 in Brain Stimulation.
Charles R. Conway, M.D., from Washington University in St. Louis, and colleagues conducted a multicenter, double-blind trial involving 493 adults with treatment-resistant major depression who were randomly assigned to receive 12 months of active or no stimulation sham VNS; 88.4 percent of participants completed the trial. The researchers found that the percent time in Montgomery-Åsberg Depression Rating Scale response could not differentiate active from sham VNS. However, antidepressant benefits significantly favored active VNS based on ratings from on-site clinicians and offsite masked raters. Significantly more percent time in response on the Clinical Global Inventory-Impression and Quick Inventory of Depressive Symptomology-Self Report was seen with active VNS.
A. John Rush, M.D., from Duke-NUS Medical School in Singapore, and colleagues compared the effects of active versus sham VNS on QoL and function in TRD in a multicenter, randomized study involving 493 adult patients with four or more unsuccessful antidepressant treatment trials. The researchers found that active VNS was superior to sham in terms of mean change from baseline in the seven-item subset of the Quality-of-Life Enjoyment and Satisfaction Questionnaire (Mini-Q-LES-Q) and Work Productivity and Activity Impairment Questionnaire (WPAI) item 6 used as continuous variables; a similar trend was seen for Q-LES-Q. Based on the Mini-Q-LES-Q, WPAI item 6, and Q-LES-Q, active VNS was superior to sham in time spent in clinically meaningful benefit.
"What's really important here is that patients themselves were reporting that their lives were improving," Conway said in a statement.
Several authors disclosed ties to pharmaceutical and medical technology companies, including LivaNova; LivaNova funded the original study from which these findings were derived.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Depression Across the Life Course Linked to Increased Risk for Dementia
TUESDAY, June 3, 2025 -- Depression across the life course is associated with an increased risk for dementia, according to a study published online May 29 in...
ASCO: Disease-Free Survival Prolonged With Exercise Program in Colon Cancer
TUESDAY, June 3, 2025 -- For patients with resected colon cancer who have completed adjuvant chemotherapy, a three-year structured exercise program results in significantly longer...
Caffeine Intake in Midlife Linked to Healthy Aging in Women
TUESDAY, June 3, 2025 -- For women, caffeine and regular coffee intake in midlife is associated with increased odds of healthy aging (HA), according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.